MEI Pharma, Inc. (MEIP) Bundle
A Brief History of MEI Pharma, Inc. (MEIP)
Company Formation and Early Years
MEI Pharma, Inc. was established in 2000 as a biotechnology company focused on advancing science to treat cancer. The company operates from its headquarters in San Diego, California.
Initial Public Offering (IPO)
MEI Pharma went public in 2013, raising approximately $22 million in its IPO. The stock began trading on the NASDAQ under the ticker symbol MEIP.
Key Developments and Milestones
- In 2015, MEI Pharma initiated clinical trials for its lead product, Pracinostat, a potential treatment for acute myeloid leukemia (AML).
- In 2017, the company announced significant progress in its Phase 2 trial for Pracinostat in combination with azacitidine.
- In 2019, the company reported $12.7 million in revenue primarily from grants and collaborations.
- By 2020, MEI Pharma raised about $57 million through an underwritten public offering.
Recent Financial Performance
As of the fiscal year ending June 30, 2023, MEI Pharma reported total revenues of approximately $17.8 million primarily from collaboration agreements. The company ended the fiscal year with cash and cash equivalents totaling around $30.5 million.
Clinical Development Pipeline
MEI Pharma has a diverse pipeline of drug candidates, including:
| Drug Candidate | Indication | Phase | Expected Milestones |
|---|---|---|---|
| Pracinostat | Acute Myeloid Leukemia | Phase 2 | Data readout in Q4 2023 |
| ME-401 | Diffuse Large B-Cell Lymphoma | Phase 2 | Interim results in mid-2024 |
| ME-344 | Ovarian Cancer | Phase 1 | Enrollment completion in 2024 |
Strategic Collaborations and Partnerships
MEI Pharma has formed several strategic partnerships to advance its research and development efforts. Notable collaborations include:
- Collaboration with AbbVie to develop combination therapies.
- Alliance with Merck KGaA for the development of ME-401.
- Joint research agreement with Vanda Pharmaceuticals focused on novel cancer therapies.
Market Position and Future Outlook
As of late 2023, MEI Pharma's market capitalization stood at approximately $250 million. The company continues to focus on expanding its pipeline and advancing its clinical trials while maintaining a strong balance sheet to support its long-term growth strategy.
A Who Owns MEI Pharma, Inc. (MEIP)
Institutional Ownership
Institutional Ownership
As of the latest reporting period, MEI Pharma, Inc. (MEIP) has significant institutional ownership. The following table outlines the largest institutional shareholders:
| Institution | Shares Owned | Percentage of Ownership | Date Reported |
|---|---|---|---|
| BlackRock, Inc. | 2,974,112 | 15.8% | September 30, 2023 |
| The Vanguard Group, Inc. | 2,501,248 | 13.4% | September 30, 2023 |
| Wellington Management Group LLP | 2,041,000 | 10.9% | September 30, 2023 |
| State Street Corporation | 1,680,000 | 9.0% | September 30, 2023 |
| Geode Capital Management, LLC | 1,440,000 | 7.7% | September 30, 2023 |
Insider Ownership
Insider ownership provides insights into the confidence of executives in the company. Below is a table summarizing the insider ownership in MEI Pharma, Inc.:
| Insider Name | Position | Shares Owned | Percentage of Ownership |
|---|---|---|---|
| Daniel P. Gold | President & CEO | 500,000 | 2.7% |
| David T. McCulloch | VP & CFO | 150,000 | 0.8% |
| Jai B. Monga | Chief Medical Officer | 100,000 | 0.5% |
Shareholder Composition
The broader shareholder composition can impact corporate governance. The table below illustrates the shareholder base of MEI Pharma, Inc.:
| Shareholder Type | Percentage of Total Shares |
|---|---|
| Institutional Investors | 54.9% |
| Insiders | 4.0% |
| Retail Investors | 41.1% |
Recent Stock Performance
Stock performance can indicate market sentiment. The following data presents the recent performance numbers for MEI Pharma, Inc. (MEIP):
| Date | Opening Price | Closing Price | Market Capitalization |
|---|---|---|---|
| October 13, 2023 | $3.15 | $3.20 | $590 million |
| October 6, 2023 | $3.10 | $3.15 | $580 million |
| September 29, 2023 | $3.00 | $3.10 | $570 million |
Latest Financial Data
The latest financial results for MEI Pharma, Inc. show the following key metrics:
| Financial Metric | Amount |
|---|---|
| Revenue (Q3 2023) | $10 million |
| Net Loss (Q3 2023) | ($5 million) |
| Cash Position (End of Q3 2023) | $50 million |
MEI Pharma, Inc. (MEIP) Mission Statement
Company Overview
MEI Pharma, Inc. focuses on the development of novel therapies for cancer treatment. The company is dedicated to addressing the unmet medical needs in oncology through innovative drug development strategies.
Core Values
- Integrity: Upholding the highest standards of ethics in all business dealings.
- Innovation: Driving advancements in cancer therapies through research and development.
- Collaboration: Partnering with medical professionals and organizations to enhance patient care.
Financial Performance
As of the third quarter of 2023, MEI Pharma reported the following financial data:
| Quarter | Net Revenue (in millions) | Net Loss (in millions) | Cash and Cash Equivalents (in millions) |
|---|---|---|---|
| Q3 2023 | 5.2 | (13.4) | 45.7 |
| Q2 2023 | 4.0 | (11.8) | 52.1 |
| Q1 2023 | 3.5 | (12.1) | 68.9 |
Pipeline Overview
MEI Pharma's pipeline includes multiple clinical-stage programs aimed at various cancer types. Key programs include:
- ME-401: A selective oral PI3K inhibitor currently in Phase 2 trials.
- Pracinostat: A histone deacetylase (HDAC) inhibitor being evaluated in combination with azacitidine.
- ME-203: An investigational therapy targeting hematologic malignancies.
Market Position
MEI Pharma operates in the competitive oncology sector, where the global cancer therapeutics market was valued at approximately $150 billion in 2021 and is projected to reach $250 billion by 2028, growing at a CAGR of 7.6%.
Commitment to Patients
MEI Pharma's mission emphasizes improving patient outcomes through:
- Clinical Research: Investing in high-quality clinical trials to bring effective therapies to market.
- Patient Engagement: Involving patients in the drug development process to better address their needs.
Recent Developments
On August 1, 2023, MEI Pharma announced positive interim results from its Phase 2 clinical trial for ME-401, indicating a 32% overall response rate among treated patients.
Strategic Partnerships
MEI Pharma has established partnerships with various research institutions and pharmaceutical companies to enhance its drug development efforts, including:
- Collaboration with the National Cancer Institute (NCI): Focusing on innovative treatment modalities.
- Agreements with other biotech firms: Aiming to expand research capabilities and access to new technologies.
Future Outlook
Looking forward, MEI Pharma aims to advance its clinical programs and expand its market presence with a focus on achieving regulatory approvals. The company has budgeted approximately $30 million for R&D expenses in FY 2024 to support ongoing trials and preclinical studies.
How MEI Pharma, Inc. (MEIP) Works
Overview
MEI Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer. The company’s primary focus is on leveraging its proprietary drug development platform to discover and advance novel therapies aimed at improving patient outcomes.
Core Products
MEI Pharma’s portfolio includes the following key product candidates:
- Pracinostat: An oral histone deacetylase inhibitor currently being evaluated in combination with azacitidine for the treatment of acute myeloid leukemia (AML). The targeted market population sees an estimated annual incidence of approximately 20,000 cases in the United States.
- ME-401: A selective PI3K delta inhibitor in clinical trials for follicular lymphoma and other B-cell malignancies.
- ME-344: An investigational agent targeting mitochondrial metabolism in cancer cells.
Market Statistics
The global cancer therapeutics market was valued at approximately $150 billion in 2020 and is projected to reach around $250 billion by 2026, with a CAGR of approximately 10%.
Recent Financial Performance
As of the fiscal year ended June 30, 2022, MEI Pharma reported:
| Financial Metric | Amount (in millions) |
|---|---|
| Revenue | $2.1 |
| R&D Expenses | $28.4 |
| General & Administrative Expenses | $12.6 |
| Net Loss | $(39.5) |
| Cash and Cash Equivalents | $40.2 |
Pipeline and Development Strategy
MEI Pharma focuses on advancing its clinical pipeline through:
- Conducting Phase 2 studies for Pracinostat in AML and other hematological malignancies.
- Implementing combination therapy trials to optimize therapeutic efficacy.
- Exploring strategic partnerships for co-development and commercialization opportunities.
Collaborations and Partnerships
As of 2023, MEI Pharma has engaged in collaborative agreements with various research institutions and pharmaceutical companies. Key partnerships include:
- Collaboration with AstraZeneca for developing combination therapies.
- Joint research initiatives with MD Anderson Cancer Center focusing on innovative treatment approaches.
Corporate Governance
MEI Pharma operates under a structured corporate governance framework, which includes:
- A Board of Directors with diverse expertise in finance, medicine, and biotechnology.
- Established committees for Audit, Compensation, and Nominating Governance.
Stock Performance
MEI Pharma, Inc. is listed on the NASDAQ under the ticker symbol MEIP. The stock performance for the last fiscal year is as follows:
| Year | Opening Price | Closing Price | Annual High | Annual Low |
|---|---|---|---|---|
| 2022 | $2.50 | $1.80 | $3.75 | $1.50 |
Future Outlook
Looking ahead, MEI Pharma aims to enhance its clinical pipeline and expand its product portfolio with a focus on delivering therapies that target unmet medical needs in oncology. Key goals include:
- Advancing Phase 2 trial results for Pracinostat by 2024.
- Exploring new indications for ME-401 in autoimmune diseases.
- Enhancing shareholder value through strategic partnerships and collaborations.
How MEI Pharma, Inc. (MEIP) Makes Money
Revenue Streams
Revenue Streams
MEI Pharma, Inc. generates revenue primarily through the development and commercialization of its oncology therapies. Their revenue model includes:
- Licensing agreements with larger pharmaceutical companies.
- Collaborative development agreements for drug development.
- Potential milestone payments and royalties from approved treatments.
Licensing Agreements
MEI Pharma engages in licensing agreements, where they partner with larger pharmaceutical firms for the development and commercialization of their proprietary drugs. For instance, in 2018, MEI entered into a strategic collaboration with Haplo Therapeutics for developing ME-401, a potent PI3K inhibitor.
Collaborative Development Agreements
Collaborative development agreements with other biotech and pharmaceutical companies allow MEI to share the financial burden of research and development. An example of this would be their collaboration with Kyowa Kirin Co., Ltd. for the development of ME-401.
Milestone Payments and Royalties
Upon achieving specific developmental milestones, MEI Pharma can receive substantial payments. For example, they could receive up to $100 million in milestone payments from collaboration agreements, depending on the success of the drug in clinical trials and subsequent approvals.
Financial Overview
As of the latest financial reports, MEI Pharma's revenue for the year 2022 was approximately $8.7 million, mainly from licensing agreements and collaboration arrangements. Their overall expenses for that year were around $35 million.
| Year | Revenue ($ million) | Expenses ($ million) | Net Income ($ million) | Cash and Cash Equivalents ($ million) |
|---|---|---|---|---|
| 2020 | 5.6 | 29.8 | -24.2 | 32.1 |
| 2021 | 6.5 | 33.6 | -27.1 | 28.4 |
| 2022 | 8.7 | 35.0 | -26.3 | 22.5 |
Market Potential
The oncology market is projected to grow significantly, with estimates forecasting a market size of $450 billion by 2028. MEI Pharma's focus on innovative therapies places them in a lucrative position for future growth.
Clinical Trials and Development Pipeline
MEI Pharma has an active pipeline of potential therapies, including:
- ME-401 (a PI3K inhibitor)
- ME-344 (an anti-cancer agent)
- Other investigational new drug applications currently in various phases of clinical trials.
As of the latest data, ME-401 is in Phase 2 clinical trials, and upon successful completion, the potential market opportunity could lead to significant revenue through future sales and licensing deals.
Investment and Capital Raises
To support its research endeavors, MEI Pharma has engaged in several funding rounds. In 2021, they raised approximately $30 million through a public offering, which was directed toward advancing their clinical development programs.
Conclusion on Financial Viability
MEI Pharma's financial strategy hinges on effectively navigating clinical trials, securing partnerships, and capitalizing on the burgeoning oncology market. Their revenue generation relies on a mixture of innovative drug development, strategic collaborations, and prudent financial management.
MEI Pharma, Inc. (MEIP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support